与白炎,梅博米腺功能障碍和沙拉齐安相关的药物:真实世界,基于人口的药监测分析
Dana Taghaddos1, Andrew Mihalache2, Ryan S Huang2
1Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Eye (London, England)
|September 9, 2025
概括
系统性药物如费纳斯特,博特佐米布和杜皮卢马布不成比例地与眼疾病,如梅博米腺功能障碍 (MGD) 和沙拉齐安有关. 临床医生应对这些不良反应进行监测,特别是在高危患者中.
科学领域:
- 眼科医生 眼科 眼科
- 药物监督 药物监督 药物监督
- 皮肤病学 皮肤病学
背景情况:
- 眼炎,梅博米腺功能障碍 (MGD) 和沙拉西亚是常见的眼疾病,影响患者的生活质量.
- 系统性药物越来越多地被认为有可能导致眼部副作用.
研究的目的:
- 为了确定不成比例地与白炎,MGD和沙拉西亚相关的全身药物.
- 分析食品和药物管理局的不良事件报告系统 (FAERS),寻找与这些眼疾病相关的安全信号.
主要方法:
- 利用FAERS从2003年第四季度到2024年第二季度的数据进行药监测分析.
- 使用报告几率比率 (RORs) 进行不成比例分析,以识别过度报告的药物.
主要成果:
- 确定了费纳斯特里德和MGD (ROR=71.6),博尔特佐米布和沙拉齐安 (ROR=73.9) 和杜皮卢马布与这三种疾病 (白炎ROR=35.7,MGDROR=15.4,沙拉齐安ROR=12.6) 之间的显著关联.
- 对白炎的安全信号还注意到异丁诺因,多塞塔克塞尔,潘蒂图穆马布,塞图西马布,特雷丁诺因,阿伦德罗纳特,埃洛提尼布,佐勒德罗纳特,达克西博胺毒素A和因弗力西马布.
结论:
- 几种全身性药物与白炎,MGD和chalazion有关,突出了眼炎的忽视的原因.
- 临床医生应保持对这些副作用的警,考虑预防措施,并教育患者眼卫生和症状报告.
相关概念视频
Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.6K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.6K
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Cholinergic Antagonists: Pharmacokinetics
908
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
908
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
1.6K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.6K
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.8K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.8K
Open Angle Glaucoma: Treatment
963
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
963


